{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:13:13Z","timestamp":1793293993823,"version":"4.5.0"},"reference-count":54,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T00:00:00Z","timestamp":1476403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2016,10,14]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The identification of individuals with latent tuberculosis infection (LTBI) is useful for both fundamental understanding of the pathogenesis of disease and for clinical and public health interventions (i.e., to prevent progression to disease). Basic research suggests there is a pathogenetic continuum from exposure to infection to disease, and individuals may advance or reverse positions within the spectrum, depending on changes in the host immunity. Unfortunately, there is no diagnostic test that resolves the various stages within the spectrum of\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    infection. Two main immune-based approaches are currently used for identification of LTBI: the tuberculin skin test (TST) and the interferon-gamma release assay (IGRA). TST can use either the conventional purified protein derivative or more specific antigens. Extensive research suggests that both TST and IGRA represent indirect markers of\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    exposure and indicates a cellular immune response to\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    . The imperfect concordance between these two tests suggests that neither test is perfect, presumably due to both technical and biological reasons. Neither test can accurately differentiate between LTBI and active TB. Both IGRA and TST have low sensitivity in a variety of immunocompromised populations. Cohort studies have shown that both TST and IGRA have low predictive value for progression from infection to active TB. For fundamental applications, basic research is necessary to identify those at highest risk of disease with a positive TST and\/or IGRA. For clinical applications, the identification of such biomarkers can help prioritize efforts to interrupt progression to disease through preventive therapy.\n                  <\/jats:p>","DOI":"10.1128\/microbiolspec.tbtb2-0023-2016","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T10:00:33Z","timestamp":1476957633000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":100,"title":["Latent\n                    <i>Mycobacterium tuberculosis<\/i>\n                    Infection and Interferon-Gamma Release Assays"],"prefix":"10.1128","volume":"4","author":[{"given":"Madhukar","family":"Pai","sequence":"first","affiliation":[{"name":"McGill International TB Center and Department of Epidemiology and Biostatistics, McGill University, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Behr","sequence":"additional","affiliation":[{"name":"McGill International TB Center and Department of Epidemiology and Biostatistics, McGill University, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"World Health Organization. 2014. The End TB Strategy. Global strategy and targets for tuberculosis prevention care and control after 2015. http:\/\/www.who.int\/tb\/post2015_TBstrategy.pdf?ua=1."},{"key":"e_1_3_2_3_2","unstructured":"Mazurek GH Jereb J Vernon A LoBue P Goldberg S Castro K IGRA Expert Committee Centers for Disease Control and Prevention (CDC). 2010. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection: United States 2010. MMWR Recomm Rep 59 (RR-5) : 1\u201325. [PubMed]"},{"key":"e_1_3_2_4_2","unstructured":"Pai M Kunimoto D Jamieson F Menzies D. 2013. Diagnosis of latent tuberculosis infection. In Canadian Tuberculosis Standards 7th Edition. Can Respir J 20: 23A\u201334A."},{"key":"e_1_3_2_5_2","unstructured":"National Institute for Health and Care Excellence. 2016. Tuberculosis. NICE guideline NG33. https:\/\/www.nice.org.uk\/guidance\/ng33. [PubMed]"},{"key":"e_1_3_2_6_2","unstructured":"World Health Organization. 2014. Guidelines on the Management of Latent Tuberculosis Infection . WHO Geneva Switzerland."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Getahun H et al. 2015. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 46: 1563\u20131576 http:\/\/dx.doi.org\/10.1183\/13993003.01245-2015. [CrossRef]","DOI":"10.1183\/13993003.01245-2015"},{"key":"e_1_3_2_8_2","unstructured":"Landry J Menzies D. 2008. Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lung Dis 12: 1352\u20131364. [PubMed]"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Barry CE III Boshoff HI Dartois V Dick T Ehrt S Flynn J Schnappinger D Wilkinson RJ Young D. 2009. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7: 845\u2013855. [PubMed][CrossRef]","DOI":"10.1038\/nrmicro2236"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Esmail H Barry CE III Wilkinson RJ. 2012. Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discov Today 17: 514\u2013521 http:\/\/dx.doi.org\/10.1016\/j.drudis.2011.12.013.","DOI":"10.1016\/j.drudis.2011.12.013"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Seddon JA. 2016. Two sizes do not fit all: the terms infection and disease are inadequate for the description of children with tuberculosis. Arch Dis Child 101: 594\u2013595 http:\/\/dx.doi.org\/10.1136\/archdischild-2016-310747. [PubMed][CrossRef]","DOI":"10.1136\/archdischild-2016-310747"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Dheda K Schwander SK Zhu B van Zyl-Smit RN Zhang Y. 2010. The immunology of tuberculosis: from bench to bedside. Respirology 15: 433\u2013450 http:\/\/dx.doi.org\/10.1111\/j.1440-1843.2010.01739.x. [PubMed][CrossRef]","DOI":"10.1111\/j.1440-1843.2010.01739.x"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Vynnycky E Fine PE. 1997. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 119: 183\u2013201 http:\/\/dx.doi.org\/10.1017\/S0950268897007917. [PubMed][CrossRef]","DOI":"10.1017\/S0950268897007917"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Andrews JR Noubary F Walensky RP Cerda R Losina E Horsburgh CR. 2012. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis . Clin Infect Dis 54: 784\u2013791 http:\/\/dx.doi.org\/10.1093\/cid\/cir951. [CrossRef]","DOI":"10.1093\/cid\/cir951"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"American Thoracic Society. 2000. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA) September 1999 and the sections of this statement. Am J Respir Crit Care Med 161: S221\u2013S247. [PubMed][CrossRef]","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Pai M Denkinger CM Kik SV Rangaka MX Zwerling A Oxlade O Metcalfe JZ Cattamanchi A Dowdy DW Dheda K Banaei N. 2014. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 27: 3\u201320 http:\/\/dx.doi.org\/10.1128\/CMR.00034-13. [CrossRef]","DOI":"10.1128\/CMR.00034-13"},{"key":"e_1_3_2_17_2","unstructured":"Menzies RI. 2000. Tuberculin skin testing p 279\u2013322. In Reichman LB Hershfield ES (ed) Tuberculosis: a Comprehensive International Approach . Marcel Dekker New York NY."},{"key":"e_1_3_2_18_2","unstructured":"Deck F Guld J. 1964. The WHO tuberculin test. Bull Int Union Tuberc 34: 53\u201370. [PubMed]"},{"key":"e_1_3_2_19_2","unstructured":"CDC (ed). 2013. Core Curriculum on Tuberculosis: What the Clinician Should Know . CDC Atlanta GA. http:\/\/www.cdc.gov\/tb\/education\/corecurr\/pdf\/chapter3.pdf."},{"key":"e_1_3_2_20_2","unstructured":"Farhat M Greenaway C Pai M Menzies D. 2006. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 10: 1192\u20131204. [PubMed]"},{"key":"e_1_3_2_21_2","unstructured":"Menzies D Gardiner G Farhat M Greenaway C Pai M. 2008. Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int J Tuberc Lung Dis 12: 498\u2013505. [PubMed]"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Zwerling A Behr MA Verma A Brewer TF Menzies D Pai M. 2011. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med 8: e1001012. doi:10.1371\/journal.pmed.1001012 http:\/\/dx.doi.org\/10.1371\/journal.pmed.1001012. [PubMed]","DOI":"10.1371\/journal.pmed.1001012"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Menzies D. 1999. Interpretation of repeated tuberculin tests. Boosting conversion and reversion. Am J Respir Crit Care Med 159: 15\u201321 http:\/\/dx.doi.org\/10.1164\/ajrccm.159.1.9801120. [PubMed][CrossRef]","DOI":"10.1164\/ajrccm.159.1.9801120"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Mahairas GG Sabo PJ Hickey MJ Singh DC Stover CK. 1996. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis . J Bacteriol 178: 1274\u20131282. [PubMed]","DOI":"10.1128\/jb.178.5.1274-1282.1996"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"S\u00f8rensen AL Nagai S Houen G Andersen P Andersen AB. 1995. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis . Infect Immun 63: 1710\u20131717. [PubMed]","DOI":"10.1128\/iai.63.5.1710-1717.1995"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","unstructured":"Andersen P Munk ME Pollock JM Doherty TM. 2000. Specific immune-based diagnosis of tuberculosis. Lancet 356: 1099\u20131104 http:\/\/dx.doi.org\/10.1016\/S0140-6736(00)02742-2. [CrossRef]","DOI":"10.1016\/S0140-6736(00)02742-2"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","unstructured":"Geluk A van Meijgaarden KE Franken KL Subronto YW Wieles B Arend SM Sampaio EP de Boer T Faber WR Naafs B Ottenhoff TH. 2002. Identification and characterization of the ESAT-6 homologue of Mycobacterium leprae and T-cell cross-reactivity with Mycobacterium tuberculosis . Infect Immun 70: 2544\u20132548 http:\/\/dx.doi.org\/10.1128\/IAI.70.5.2544-2548.2002. [CrossRef]","DOI":"10.1128\/IAI.70.5.2544-2548.2002"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Geluk A van Meijgaarden KE Franken KL Wieles B Arend SM Faber WR Naafs B Ottenhoff TH. 2004. Immunological crossreactivity of the Mycobacterium leprae CFP-10 with its homologue in Mycobacterium tuberculosis . Scand J Immunol 59: 66\u201370 http:\/\/dx.doi.org\/10.1111\/j.0300-9475.2004.01358.x. [CrossRef]","DOI":"10.1111\/j.0300-9475.2004.01358.x"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","unstructured":"Pollock L Basu Roy R Kampmann B. 2013. How to use: interferon \u03b3 release assays for tuberculosis. Arch Dis Child Educ Pract Ed 98: 99\u2013105 http:\/\/dx.doi.org\/10.1136\/archdischild-2013-303641. [PubMed][CrossRef]","DOI":"10.1136\/archdischild-2013-303641"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","unstructured":"Hoffmann H Avsar K G\u00f6res R Mavi SC Hofmann-Thiel S. 2016. Equal sensitivity of the new generation QuantiFERON-TB Gold plus in direct comparison with the previous test version QuantiFERON-TB Gold IT. Clin Microbiol Infect 22: 701\u2013703. [PubMed][CrossRef]","DOI":"10.1016\/j.cmi.2016.05.006"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","unstructured":"Pai M Riley LW Colford JM Jr. 2004. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 4: 761\u2013776 http:\/\/dx.doi.org\/10.1016\/S1473-3099(04)01206-X. [PubMed][CrossRef]","DOI":"10.1016\/S1473-3099(04)01206-X"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","unstructured":"Pai M Sotgiu G. 2016. Diagnostics for latent TB infection: incremental not transformative progress. Eur Respir J 47: 704\u2013706 http:\/\/dx.doi.org\/10.1183\/13993003.01910-2015. [PubMed][CrossRef]","DOI":"10.1183\/13993003.01910-2015"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","unstructured":"Sester M Sotgiu G Lange C Giehl C Girardi E Migliori GB Bossink A Dheda K Diel R Dominguez J Lipman M Nemeth J Ravn P Winkler S Huitric E Sandgren A Manissero D. 2011. Interferon-\u03b3 release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 37: 100\u2013111 http:\/\/dx.doi.org\/10.1183\/09031936.00114810. [CrossRef]","DOI":"10.1183\/09031936.00114810"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","unstructured":"Mack U Migliori GB Sester M Rieder HL Ehlers S Goletti D Bossink A Magdorf K H\u00f6lscher C Kampmann B Arend SM Detjen A Bothamley G Zellweger JP Milburn H Diel R Ravn P Cobelens F Cardona PJ Kan B Solovic I Duarte R Cirillo DM C Lange for the TBNET. 2009. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis ? A TBNET consensus statement. Eur Respir J 33: 956\u2013973 http:\/\/dx.doi.org\/10.1183\/09031936.00120908. [CrossRef]","DOI":"10.1183\/09031936.00120908"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","unstructured":"Rangaka MX Wilkinson KA Glynn JR Ling D Menzies D Mwansa-Kambafwile J Fielding K Wilkinson RJ Pai M. 2012. Predictive value of interferon-\u03b3 release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 12: 45\u201355 http:\/\/dx.doi.org\/10.1016\/S1473-3099(11)70210-9. [CrossRef]","DOI":"10.1016\/S1473-3099(11)70210-9"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","unstructured":"Slater ML Welland G Pai M Parsonnet J Banaei N. 2013. Challenges with QuantiFERON-TB Gold assay for large-scale routine screening of U.S. healthcare workers. Am J Respir Crit Care Med 188: 1005\u20131010 http:\/\/dx.doi.org\/10.1164\/rccm.201305-0831OC. [PubMed][CrossRef]","DOI":"10.1164\/rccm.201305-0831OC"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","unstructured":"Dorman SE Belknap R Graviss EA Reves R Schluger N Weinfurter P Wang Y Cronin W Hirsch-Moverman Y Teeter LD Parker M Garrett DO Daley CL Tuberculosis Epidemiologic Studies Consortium. 2014. Interferon-\u03b3 release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med 189: 77\u201387. [PubMed]","DOI":"10.1164\/rccm.201302-0365OC"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","unstructured":"Zwerling A Benedetti A Cojocariu M McIntosh F Pietrangelo F Behr MA Schwartzman K Menzies D Pai M. 2013. Repeat IGRA testing in Canadian health workers: conversions or unexplained variability? PLoS One 8: e54748. doi:10.1371\/journal.pone.0054748 http:\/\/dx.doi.org\/10.1371\/journal.pone.0054748. [PubMed][CrossRef]","DOI":"10.1371\/journal.pone.0054748"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","unstructured":"Joshi M Monson TP Joshi A Woods GL. 2014. IFN-\u03b3 release assay conversions and reversions: challenges with serial testing in U.S. health care workers. Ann Am Thorac Soc 11: 296\u2013302 http:\/\/dx.doi.org\/10.1513\/AnnalsATS.201310-378OC. [PubMed][CrossRef]","DOI":"10.1513\/AnnalsATS.201310-378OC"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","unstructured":"Tagmouti S Slater M Benedetti A Kik SV Banaei N Cattamanchi A Metcalfe J Dowdy D van Zyl Smit R Dendukuri N Pai M Denkinger C. 2014. Reproducibility of interferon gamma (IFN-\u03b3) release assays: a systematic review. Ann Am Thorac Soc 11: 1267\u20131276 http:\/\/dx.doi.org\/10.1513\/AnnalsATS.201405-188OC. [PubMed][CrossRef]","DOI":"10.1513\/AnnalsATS.201405-188OC"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","unstructured":"Banaei N Gaur RL Pai M. 2016. Interferon-gamma release assays for latent tuberculosis: what are the sources of variability? J Clin Microbiol 54: 845\u2013850 http:\/\/dx.doi.org\/10.1128\/JCM.02803-15. [PubMed][CrossRef]","DOI":"10.1128\/JCM.02803-15"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","unstructured":"Pai M Banaei N. 2013. Occupational screening of health care workers for tuberculosis infection: tuberculin skin testing or interferon-\u03b3 release assays? Occup Med (Lond) 63: 458\u2013460 http:\/\/dx.doi.org\/10.1093\/occmed\/kqt105.","DOI":"10.1093\/occmed\/kqt105"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","unstructured":"Daley CL Reves RR Beard MA Boyle J Clark RB Beebe JL Catanzaro A Chen L Desmond E Dorman SE Hudson TW Lardizabal AA Kapoor H Marder DC Miranda C Narita M Reichman L Schwab D Seaworth BJ Terpeluk P Thanassi W Kawamura LM. 2013. A summary of meeting proceedings on addressing variability around the cut point in serial interferon-\u03b3 release assay testing. Infect Control Hosp Epidemiol 34: 625\u2013630 http:\/\/dx.doi.org\/10.1086\/670635. [CrossRef]","DOI":"10.1086\/670635"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","unstructured":"Aggerbeck H Giemza R Joshi P Tingskov PN Hoff ST Boyle J Andersen P Lewis DJ. 2013. Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M. tuberculosis infection. PLoS One 8: e64215. doi:10.1371\/journal.pone.0064215 http:\/\/dx.doi.org\/10.1371\/journal.pone.0064215. [CrossRef]","DOI":"10.1371\/journal.pone.0064215"},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","unstructured":"Bergstedt W Tingskov PN Thierry-Carstensen B Hoff ST Aggerbeck H Thomsen VO Andersen P Andersen AB. 2010. First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent. PLoS One 5: e11277. doi:10.1371\/journal.pone.0011277 http:\/\/dx.doi.org\/10.1371\/journal.pone.0011277. [PubMed][CrossRef]","DOI":"10.1371\/journal.pone.0011277"},{"key":"e_1_3_2_46_2","unstructured":"Kiselev VI Baranovskii PM Rudykh IV Shuster AM Mart\u2019ianov VA Mednikov BL Demin AV Aleksandrov AN Mushkin AI Levi DT Slogotskaia LV Ovsiankina ES Medunitsin NV Litvinov VI Perel\u2019man MI Pal\u2019tsev MA. 2009. Clinical trials of the new skin test Diaskintest for the diagnosis of tuberculosis. Probl Tuberk Bolezn Legk 2009 (2) : 11\u201316. [In Russian.] [PubMed]"},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","unstructured":"Sun QF Xu M Wu JG Chen BW Du WX Ding JG Shen XB Su C Wen JS Wang GZ. 2013. Efficacy and safety of recombinant Mycobacterium tuberculosis ESAT-6 protein for diagnosis of pulmonary tuberculosis: a phase II trial. Med Sci Monit 19: 969\u2013977 http:\/\/dx.doi.org\/10.12659\/MSM.889425. [CrossRef]","DOI":"10.12659\/MSM.889425"},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","unstructured":"Hoff ST Peter JG Theron G Pascoe M Tingskov PN Aggerbeck H Kolbus D Ruhwald M Andersen P Dheda K. 2016. Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. Eur Respir J 47: 919\u2013928 http:\/\/dx.doi.org\/10.1183\/13993003.01464-2015. [PubMed][CrossRef]","DOI":"10.1183\/13993003.01464-2015"},{"key":"e_1_3_2_49_2","unstructured":"Centers for Disease Control and Prevention (CDC). 2013. Extent and effects of recurrent shortages of purified-protein derivative tuberculin skin test antigen solutions: United States 2013. MMWR Morb Mortal Wkly Rep 62: 1014\u20131015. [PubMed]"},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","unstructured":"Denkinger CM Dheda K Pai M. 2011. Guidelines on interferon-\u03b3 release assays for tuberculosis infection: concordance discordance or confusion? Clin Microbiol Infect 17: 806\u2013814 http:\/\/dx.doi.org\/10.1111\/j.1469-0691.2011.03555.x. [CrossRef]","DOI":"10.1111\/j.1469-0691.2011.03555.x"},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","unstructured":"Pai M Elwood K. 2012. Interferon-gamma release assays for screening of health care workers in low tuberculosis incidence settings: dynamic patterns and interpretational challenges. Can Respir J 19: 81\u201383 http:\/\/dx.doi.org\/10.1155\/2012\/420392. [CrossRef]","DOI":"10.1155\/2012\/420392"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","unstructured":"Gardiner JL Karp CL. 2015. Transformative tools for tackling tuberculosis. J Exp Med 212: 1759\u20131769 http:\/\/dx.doi.org\/10.1084\/jem.20151468. [PubMed][CrossRef]","DOI":"10.1084\/jem.20151468"},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","unstructured":"Zak DE Penn-Nicholson A Scriba TJ Thompson E Suliman S Amon LM Mahomed H Erasmus M Whatney W Hussey GD Abrahams D Kafaar F Hawkridge T Verver S Hughes EJ Ota M Sutherland J Howe R Dockrell HM Boom WH Thiel B Ottenhoff TH Mayanja-Kizza H Crampin AC Downing K Hatherill M Valvo J Shankar S Parida SK Kaufmann SH Walzl G Aderem A Hanekom WA ACS and GC6-74 cohort study groups. 2016. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 387: 2312\u20132322 doi:10.1016\/S0140-6736(15)01316-1. [CrossRef]","DOI":"10.1016\/S0140-6736(15)01316-1"},{"key":"e_1_3_2_54_2","unstructured":"Stop TB Partnership\u2019s New Diagnostics Working Group. 2016. Draft target product profile: test for progression of tuberculosis infection.http:\/\/www.finddx.org\/wp-content\/uploads\/2016\/05\/TPP-LTBIprogression.pdf."},{"key":"e_1_3_2_55_2","unstructured":"FIND McGill International TB Centre UNITAID. 2015. TB Diagnostics Market in Select High-Burden Countries: Current Market and Future Opportunities for Novel Diagnostics . UNITAID Geneva Switzerland. http:\/\/unitaid.org\/images\/marketdynamics\/publications\/TB_Diagnostics_Market_in_Select_High-Burden_Countries_Current_Market_and_Future_Opportunities_for__Novel_Diagnostics.pdf."}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/microbiolspec.TBTB2-0023-2016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/microbiolspec.TBTB2-0023-2016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T01:20:17Z","timestamp":1646702417000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/microbiolspec.TBTB2-0023-2016"}},"subtitle":[],"editor":[{"given":"William R.","family":"Jacobs Jr.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Helen","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Valerie","family":"Mizrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Ian M.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,10,14]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10,14]]}},"alternative-id":["10.1128\/microbiolspec.TBTB2-0023-2016"],"URL":"https:\/\/doi.org\/10.1128\/microbiolspec.tbtb2-0023-2016","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,14]]},"assertion":[{"value":"2016-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-10-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"4.5.24"}}